Q-code: Temporary codes Temporary codes
644 codes
Billing context
Q-codes are temporary national codes recognized by Medicare. For drugs they include biosimilar products (Q51xx) and other drugs, biologicals, and skin substitutes that are not yet assigned a permanent code. Units follow the dosage in the descriptor.
| Code | Long descriptor | Payment limit (Q4 2026) | Added | Status |
|---|---|---|---|---|
| Q4432 | 510(k) skin substitute product, not otherwise specified (list in addition to primary procedure)NOC / NOS | — | Jan 1, 2026 | Active |
| Q4433 | 361 hct/p skin substitute product, not otherwise specified (list in addition to primary procedure)NOC / NOS | — | Jan 1, 2026 | Active |
| Q4435 | Renati membrane, per square centimeter (add-on, list separately in addition to primary procedure) | — | Apr 1, 2026 | Active |
| Q4436 | Renati ac membrane, per square centimeter (add-on, list separately in addition to primary procedure) | — | Apr 1, 2026 | Active |
| Q4437 | Revival ac, per square centimeter (add-on, list separately in addition to primary procedure) | — | Apr 1, 2026 | Active |
| Q4438 | Pretect, per square centimeter (add-on, list separately in addition to primary procedure) | — | Apr 1, 2026 | Active |
| Q4439 | Instagraft, per square centimeter (add-on, list separately in addition to primary procedure) | — | Apr 1, 2026 | Active |
| Q4440 | Curamatrix, per square centimeter (add-on, list separately in addition to primary procedure) | — | Apr 1, 2026 | Active |
| Q5001 | Hospice or home health care provided in patient's home/residence | — | Jan 1, 2007 | Active |
| Q5002 | Hospice or home health care provided in assisted living facility | — | Jan 1, 2007 | Active |
| Q5003 | Hospice care provided in nursing long term care facility (ltc) or non-skilled nursing facility (nf) | — | Jan 1, 2007 | Active |
| Q5004 | Hospice care provided in skilled nursing facility (snf) | — | Jan 1, 2007 | Active |
| Q5005 | Hospice care provided in inpatient hospital | — | Jan 1, 2007 | Active |
| Q5006 | Hospice care provided in inpatient hospice facility | — | Jan 1, 2007 | Active |
| Q5007 | Hospice care provided in long term care facility | — | Jan 1, 2007 | Active |
| Q5008 | Hospice care provided in inpatient psychiatric facility | — | Jan 1, 2007 | Active |
| Q5009 | Hospice or home health care provided in place not otherwise specified (nos)NOC / NOS | — | Jan 1, 2007 | Active |
| Q5010 | Hospice home care provided in a hospice facility | — | Oct 1, 2010 | Active |
| Q5098 | Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg | $9.270per 1 MG | Jul 1, 2025 | Active |
| Q5099 | Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg | $2.890per 1 MG | Jul 1, 2025 | Active |
| Q5100 | Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg | $3.080per 1 MG | Jul 1, 2025 | Active |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | $0.338per 1 MCG | Jul 1, 2015 | Active |
| Q5102 | Injection, infliximab, biosimilar, 10 mg | — | Jul 1, 2016 | Ended Mar 31, 2018 |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | $28.456per 10 MG | Apr 1, 2018 | Active |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | $25.649per 10 MG | Apr 1, 2018 | Active |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units | $0.817per 100 UNITS | Jul 1, 2018 | Active |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | $8.171per 1000 UNITS | Jul 1, 2018 | Active |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | $28.294per 10 MG | Jan 1, 2019 | Active |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | $55.964per 0.5 MG | Oct 1, 2018 | Active |
| Q5109 | Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg | — | Jan 1, 2019 | Ended Dec 31, 2025 |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | $0.329per 1 MCG | Oct 1, 2018 | Active |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | $128.967per 0.5 MG | Jan 1, 2019 | Active |
| Q5112 | Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg | $32.791per 10 MG | Jul 1, 2019 | Active |
| Q5113 | Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg | $55.295per 10 MG | Jul 1, 2019 | Active |
| Q5114 | Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg | $29.507per 10 MG | Jul 1, 2019 | Active |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | $35.988per 10 MG | Jul 1, 2019 | Active |
| Q5116 | Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg | $11.271per 10 MG | Oct 1, 2019 | Active |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | $63.871per 10 MG | Oct 1, 2019 | Active |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | $25.939per 10 MG | Oct 1, 2019 | Active |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | $5.792per 10 MG | Jul 1, 2020 | Active |
| Q5120 | Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg | $302.247per 0.5 MG | Jul 1, 2020 | Active |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | $34.686per 10 MG | Jul 1, 2020 | Active |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | $141.289per 0.5 MG | Jan 1, 2021 | Active |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | $21.083per 10 MG | Jul 1, 2021 | Active |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | $249.493per 0.1 MG | Apr 1, 2022 | Active |
| Q5125 | Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | $0.308per 1 MCG | Oct 1, 2022 | Active |
| Q5126 | Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | $79.982per 10 MG | Jan 1, 2023 | Active |
| Q5127 | Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg | $163.948per 0.5 MG | Apr 1, 2023 | Active |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | $81.130per 0.1 MG | Apr 1, 2023 | Active |
| Q5129 | Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | $21.139per 10 MG | Apr 1, 2023 | Active |
| Q5130 | Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg | $94.292per 0.5 MG | Apr 1, 2023 | Active |
| Q5131 | Injection, adalimumab-aacf (idacio), biosimilar, 20 mg | — | Jul 1, 2023 | Ended Dec 31, 2024 |
| Q5132 | Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg | — | Jan 1, 2024 | Ended Dec 31, 2024 |
| Q5133 | Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg | $4.706per 1 MG | Apr 1, 2024 | Active |
| Q5134 | Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg | $24.397per 1 MG | Apr 1, 2024 | Active |
| Q5135 | Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg | $4.370per 1 MG | Oct 1, 2024 | Active |
| Q5136 | Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg | $26.991per 1 MG | Oct 1, 2024 | Active |
| Q5137 | Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mg | — | Jul 1, 2024 | Active |
| Q5138 | Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg | $2.273per 1 MG | Jul 1, 2024 | Active |
| Q5139 | Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg | — | Jan 1, 2025 | Ended Mar 31, 2025 |
| Q5140 | Injection, adalimumab-fkjp, biosimilar, 1 mg | — | Jan 1, 2025 | Active |
| Q5141 | Injection, adalimumab-aaty, biosimilar, 1 mg | — | Jan 1, 2025 | Active |
| Q5142 | Injection, adalimumab-ryvk biosimilar, 1 mg | — | Jan 1, 2025 | Active |
| Q5143 | Injection, adalimumab-adbm, biosimilar, 1 mg | — | Jan 1, 2025 | Active |
| Q5144 | Injection, adalimumab-aacf (idacio), biosimilar, 1 mg | — | Jan 1, 2025 | Active |
| Q5145 | Injection, adalimumab-afzb (abrilada), biosimilar, 1 mg | — | Jan 1, 2025 | Active |
| Q5146 | Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg | $30.255per 10 MG | Jan 1, 2025 | Active |
| Q5147 | Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg | $763.376per 1 MG | Apr 1, 2025 | Active |
| Q5148 | Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram | $1.026per 1 MCG | Apr 1, 2025 | Active |
| Q5149 | Injection, aflibercept-abzv (enzeevu), biosimilar, 1 mg | — | Apr 1, 2025 | Active |
| Q5150 | Injection, aflibercept-mrbb (ahzantive), biosimilar, 1 mg | — | Apr 1, 2025 | Active |
| Q5151 | Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg | $31.547per 2 MG | Apr 1, 2025 | Active |
| Q5152 | Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg | $40.412per 2 MG | Apr 1, 2025 | Active |
| Q5153 | Injection, aflibercept-yszy (opuviz), biosimilar, 1 mg | — | Jul 1, 2025 | Active |
| Q5154 | Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg | — | Oct 1, 2025 | Active |
| Q5155 | Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg | — | Oct 1, 2025 | Active |
| Q5156 | Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg | $3.098per 1 MG | Oct 1, 2025 | Active |
| Q5157 | Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg | $24.002per 1 MG | Oct 1, 2025 | Active |
| Q5158 | Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg | $28.702per 1 MG | Oct 1, 2025 | Active |
| Q5159 | Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg | — | Oct 1, 2025 | Active |
| Q5160 | Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg | $82.139per 10 MG | Jan 1, 2026 | Active |
| Q5161 | Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg | $27.509per 1 MG | Apr 1, 2026 | Active |
| Q5162 | Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg | $15.336per 1 MG | Apr 1, 2026 | Active |
| Q5164 | Injection, ustekinumab-hmny (starjemza), biosimilar, 1 mg | — | Jul 1, 2026 | Active |
| Q5165 | Injection, denosumab-mobz (oziltus), biosimilar, 1 mg | — | Jul 1, 2026 | Active |
| Q5166 | Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg | — | Jul 1, 2026 | Active |
| Q5167 | Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg | $7.681per 1 MG | Jul 1, 2026 | Active |
| Q5168 | Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg | $26.384per 0.1 MG | Jul 1, 2026 | Active |
| Q5169 | Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg | $519.481per 0.5 MG | Jul 1, 2026 | Active |
| Q5170 | Injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg | — | Jul 1, 2026 | Active |
| Q5171 | Injection, denosumab-mobz (boncresa), biosimilar, 1 mg | — | Jul 1, 2026 | Active |
| Q5172 | Injection, filgrastim-laha (filkri), biosimilar, 1 microgram | — | Oct 1, 2026 | Active |
| Q5173 | Injection, denosumab-adet (ponlimsi), biosimilar, 1 mg | — | Oct 1, 2026 | Active |
| Q9001 | Assessment by chaplain services | — | Oct 1, 2020 | Active |
| Q9002 | Counseling, individual, by chaplain services | — | Oct 1, 2020 | Active |
| Q9003 | Counseling, group, by chaplain services | — | Oct 1, 2020 | Active |
| Q9004 | Department of veterans affairs whole health partner services | — | Oct 1, 2021 | Active |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | $18.052per 1 ML | Jan 1, 2016 | Active |
| Q9951 | Low osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml | — | Apr 1, 2005 | Active |
| Q9953 | Injection, iron-based magnetic resonance contrast agent, per ml | — | Apr 1, 2005 | Active |